Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.King Pharmaceuticals and Acura Pharmaceuticals are planning to develop and submit a new drug application (NDA) for Acurox (oxycodone HC1) tablets (without niacin) intended to relieve moderate to severe pain and introduce limits and impediments to potential abuse via nasal snorting of crushed tablets and intravenous injection of dissolved tablets.
Subscribe to our email newsletter
Both the entities said that on April 22, 2010 at joint advisory committee meeting, FDA questioned the effectiveness of niacin included in the current Acurox formulation but cited no concerns with the snorting and intravenous abuse limiting features of the product. The companies expect to submit an NDA for Acurox tablets (without niacin) in early 2011.
King Pharmaceuticals and Acura are also planing to develop and submit NDA’s for two additional immediate release opioid analgesic products utilising Acura’s proprietary Aversion Technology; Vycavert (hydrocodone bitartrate/acetaminophen) tablets and Acuracet (oxycodone HCl/acetaminophen) tablets.
Like Acurox, these additional product candidates are patent protected compositions comprising a mixture of active and inactive ingredients intended to relieve pain and introduce limits and impediments to nasal and intravenous abuse.